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EPIDEMIOLOGIC STUDIES
Lipoprotein Cholesterol, Apolipoprotein A-I and B and Lipoprotein (a)
Abnormalities in Men With Premature Coronary Artery Disease
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The prevalence of abnormalities of lipoprotein cholesterol and
apollpopratelns A-I and B and Ilpoproteln (a) [Lp(a)] was deter-
mlined In 321 men (mean age 50 ± 7 years) with aagiographicelly
documented coronary artery disease and compared with that in
901 control subjects from the Framlngham (IBvpring Stud) (mean
age 49 A 6 years) who were clinically free of coronary artery
disease. After correction far sampling In hospital, hem-adrenerglc
medication use and elects ofdiel,patientshad$gnlUnruly higher
cholesterol levels (224 ± 53 vs . 214 ± 36 mgldl), triglycerides (189
± 95 vs. 141 ± 104 mgld0, low density ipoprotee (LDL)
cholesterol (156 t 51 vs . 138 3 33 mgldl), apolipoprote[n B (131
m 37 vs. 108 ± 33 agldl) and Lp(a) levels
(19
.9 *- t9 vs. 14.9 ±
17.5 mg/dl)
. They also had significantly lower high density lipo-
protein (HDL) cholesterol (36 A 11 vs . 45 ± 12 mgldl) and
apolipoprolein A-] levels (114 ± 26 vs
. 136
4
32 mg'dl) (all p <
0.005).
On the basis of Lipid Research Clinic 91hh percentile values for
triglyeerides and LIIL cholesterol and 10th percentile salons for
HDL cholesterol, the most Eloquent dysip[dendas were low HDL
The leading cause of morbidity and mortality in the United
States is coronary artery disease and its sequelae
. The
identification of subjects at risk of developing coronary
atherosclersis is an important public health issue- In addi-
tion to other risk factors, such as male gender, increasing
age, hypertension, diabetes and a family history of prema-
ture coronary artery disease, elevated plasma law density
lipoprotein (LDL) cholesterol and decreased high density
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cholesterol alone (19.3% vs . 4 .4%), elevated LDL cholesterol
(12.1% vs . 9%), hypenrlglycerldemla with law HDL cholesterol
49.7% vs. 4.2%), hypertritdyceridenda and elevated LDL choles .
treel with low HDL cholesterol (3,4% vs . 0.2%) and Lp(a) excess
(15.8% vs . 10%) In patients versus control subjects, respectively
(p < 0.05) . Stepwise diseriminant analysis Indicates that smoking,
hypertension, decreased apollpoprateh A-I, Increased apollpo-
protein B, increased Lp(a) and diabetes are all significant (p <
0.051 factors in descending order of importance in distinguishing
patients with coronary artery disease from normal control sub
jests.
Not applying a correction for hem-adrenergic blocking agents,
sampling bias and diet effects leads to a serious underestimation of
the prevalence of LDL abnormalities and an overestimation of
HDL abnormalities in patients with coronary artery disease .
However, 35% of patients had a found cholesterol level <200 mg/dl
alter correction ; of (hose patients, 73% had an HDL cholesterol
level <35 mg/dl,
(J Am Call Curdiol 1992,19c792-802)
lipoprotein (HDL) cholesterol have been shown to be inde-
pendent predictors for coronary artery disease in prospec-
tive (I-11) and case-control (12-44) epidemiologic studies .
In view of the muhifaelorial etiology of coronary atheroscle-
rosis, no single biochemical variable will identify all patients
at risk for developing coronary atherosclerosis . The effects
of the various risk factors are clearly cumulative and the
identification of mstjor biochemical markers and their inter-
relations should allow earlier detection of patients at risk
(4,45).
Elevated LDL cholesterol and decreased HDL choles-
terol concentrations are associated with an increased risk of
developing coronary artery disease 1). The major
apolipoprotcins of LUL and HDL particles, namely, ape
lipoprotein B and apolipoprotein A-1, respectively, are
strongly associated with the presence of coronary artery
disease. An increased level of LDL apolipopretein B has
been associated with increased risk, as has a low level of
apolipoprotein A-1 (13-33,36-41,43,44). Lipoprotein (a)
[Lp(a)], first identified by Berg (46), has been shown to be
increased in patients wish angiograplically documented coro-
nary artery disease (47-53) . Lp(a) consists of one or more
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molecules of ape opretein(a ;linkedbyacysteinebondtothe
apalipoprolein B moiety of LDL particle, . Recently (14.55) .
the molecular structure and complementary DNA I'DNAI of
apolipoprolein fal have been elucidated and have revealed
considerable homology between the plasminogen and epalipo-
protein (a) genes. Variant forms of apolipcitiowin in) differ in
apparent molecular weight, in part because of varying numbers
of kringle-like domains in the molecule 1561.
Our ability to measure lipoproteins, npolipoproteins and
Lp(a) has been greatly refined in the past few years. These
variables are used in many studies to provide an assessment of
cardiovascular risk in a given population . Most of these varia-
bles, however, are closely interrelated and their measuronent
may not improve our ability to predict risk. The present study
was undertaken to deterrrune lipid, lipoprotein nod apolipooro-
tein concentrntinns and the prevalence of ahnorealitiea is
li oprerein h--Qslemh apolipoproteins A-1 and B and Lgla) in
men with premature coronary artery disease, we also cor-
rected for confounding variables that affect lipid and hpopro-
tern levels, such as the effect of sampling in the hospital (57,58),
the use of medication-especially beta-adrenergic blocking
drugs (59-62)-and the role of dietary changes in am patients
(631
. We also studied the interrelations among the variables and
determined the most discdminantva•i
-
.h!as'resenceof
coronary artery disease.
Methods
Subjects studied. Patients In = 3211 underwent elective
cardiac catheterization and coronary angiognaphy for the
diagnosis and determination of the extent of coronary artery
disease at the New England Medical Center Hospital . The
referral base of the hospital includes Greater Boston and
Eastern Massachusetts
. All patients were white men <60
years of age (mean x SD 50 a 71 at the time of coronary
angiography
. All were studied between July 1985 and De-
cember 1987. Patients with acute myocardial infarction,
surgery or trauma in the 6 weeks preceding admission were
excluded . as were those taking lipid-lowering medications
.
Information on other risk factors-hypertension (defined as
a history of high blood pressure
_I%95
mm Hg . treated ur
not), diabetes (history of diabetes or treatment with an oral
hypoglycemic agent or insulin) and smoking
()t 10 cigarettes)
day in the year preceding the procedure) . as well as medi-
cations (especially diuretic drugs . beta-adrenergic blocking
agents and calcium channel blocking drugs)-wars noted by
direct interview and review of the patient's medical chart .
The degree of coronary artery disease was determined by
two independent cardiologists unaware of the patient's in-
clusion in the study. The presence of coronary artery dis-
ease . defined as
>S11fo stenosis of a major coronary artery .
was identified on multiple projections (>75fa cross-sectional
area stenosis) . Patients with minimal disease (<509h steno
sis) or with normal angwgrams (n = 25) were excluded from
the analysis . The study protocol was reviewed and accepted
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by the Hun- lncestigation Review Committee of the New
Lngiand Medical Center.
Men in = 901) 49 *_ 6 years of age from the offspring
cohort of the Framingham Heart Study were used as control
subjects. These control subjects were free of clinical mani-
festations of eerebrovnseulnr, peripheral vascular or taro-
nary artery disease and had no history of myocardial infarc-
tion . Information on risk factors and medication as for the
study patients was ascertained. Subjects with clinically
documented cardiovascular disease (angina, definite or sus-
pecled myocardial infarction,eledrocardiographic evidence
of myocardial infarction, peripheral vascular disease or
uerebrovascular disease) were excluded . Control subjects
taking lipid-lowering medications were excluded .
Lipid, lipoprotein, apoIlpoproteiu ant Lp(al measure.
mentor Plasma Iola]cholesterol . triglyceridcsandHDLchn-
lesterol levels were determined enzymatically, with HDL
cholesterol determined after dextran-magnesium precipita-
tiuu
. LDL ~hnlestenal was calculated by the method of
Friedewald et al . (64) unless the tergiycetiuu wacenuration
was r400
mgidl . i
n which case, cholesterol was measured in
the d > 1
.606 infranate after ullmcentrifugation (65 .66)
. LDL
cholesterol was then calculated as infranate cholesterol
minas HDL cholesterol . Lipid analyses were performed at
the Lipid Metabolism Laboratory of the U
.S . Department of
Agriculture Human Nutrition Research Center no Aping at
Tufts University, and at the Framingham Heart Study Core
Laboratory. Both laboratories use identical procedures and
equipment . Ourlaboratory, meets the performance criteria of
the Centers for Disease Control Lipid Standardization fro-
gram (651 . Multiple aliquots of plasma were frozen at -80'C
for later analysis of apolipoproteins .
Apolipoprorein A-f end afrelipoprolein B were measured
by noncompetitive enzyme-linked immunosorbent assays
(ELISA) (67.69). Normal ranges forapulipoproteins A-I and
B were determined in 3 .541 participolds (men and women)
from the Framingham Offspring Study- Apnlipoprotein im-
munoassays were standadzed with use of purified apolipo-
proteins subjected to amino acid analysis. Lp(a) was deter-
mined by ELISA, with use ofa monoclonal anti-Lp(a) antibody
with no cress-reactivity to plasminogen and a pulyclunal anti-
body directed at the apulipoprolein (a) portion of Lp(a) [Macro
Lp(a), Tenlmu Corp
.] . This assay was standardized with use of
purified Lp(a), with the mass corresponding to the entire
particle . Lpla) levels were determined in 760 male control
subjects and 256 men with coronary artery disease ; lack of
plasma samples accounts for the missing values . The 90th
percentile far Lplal
. based on the contra) group- was deter-
mined to be 39.8 mg dl
. All apnlipoprotein and Lp(a) determi-
nations were performed at the Lipid Metabolism Laboratory at
Tufts University, Intm-and intermit coefficients ofvariance for
these assays were <10%.
Did elfeets
. We attempted to correct for a possible diet
effect by analyzing the nutrient intake (as a percent of
calories) in 43 wren with coronary artery disease and 96
Framingham control subjects by using feed frequency ques-
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tionnaires (69)
.
The coronary artery disease group had
slightly lower total tat consumption than did the control
group (29 .3% vs. 32.1%), with the following differences in
saturated . monosaturated and polyunsaturated fats : 10 .2%
vs . 12_9%; 11 .4% vs. 13 .3% and 8.6% vs. 5
.9%, respectively .
The daily cholesterol intake was 105 vs . 150 mg1l,000 kenl .
By applying the formula of Hegsted et al. (70) to determine
the change in total cholesterol, patients with coronary artery
disease would be expected to have a 6 .6% decrease in total
cholesterol. On the basis of this subset analysis, we extrap-
olated the effects of diet to the coronary artery disease group
and made the following assumptions: the effect of the diet
was the same for all patients (that is, a decrease of 6 .6% in
total cholesterol due to a decrease in LDL cholesterol),
apofpes ro7e ;a B changed to the some degree as LDL
cholesterol and there was no significant effect overall on
.riglycedde HDL cholesterol apolipoprotein A-I or Lp(a)
levels
. Body mass index was calculated as weight (kg)l
height'- (cm).
Statistical analysis, The data were stored on a VAX
111780 computer (Digital Equipment Corp .) with use of the
database RS/1(BBN Software). The normality of continuous
lipoprotein measures was tested by using the Kolmogorov-
Smirnoff test . Triglycerides and Lpta) levels were trans-
formed ey using log ln to better approximate a normal distri-
butionThe group-, d est was used tocompare atient and
control groups for these variables . Unpaired two-tailed r
tests were used to evaluate the differences between mean
values for variables having a parametric distribution . Log1o
transformation of nonparametric variables was performed
and the r test was then used . Chi-square analysis was used to
evaluate the differences in smoking, diabetes, hypertension
and use of heta-blockers, as well as differences in prevalence
of lipid disorders . Multiple regression analyses were con-
ducted by using the Statistical Analysis Software (SAS)
package to determine correlation coefficients between the
clinical data and lipid analyses . We corrected for noted
beta-blocker effect, in-hospital sampling bias and diet effect
and calculated the expected changes in lipid . lipoprotein
cholesterol and apolipoprotein A-I and B levels
. The Spear-
man correlation coefficients were used for variables not
having a normal distribution . Stepwise discriminant analysis
was performed by using a forward/backward procedure with
hypertension, smoking, diabetes, triglycerides and lipopro-
tein cholesterol levels or apolipoprotein values entered into
the statistical model .
Results
Clinical data (Table 11
. The mean age of the coronary
artery disease and control groups was virtually identical,
although a statistically significant difference was detected (50
± 7 vs . 49 ± 6 years, patients vs . control subjects, p
0 .046)
. The prevalence of hypertension was higher in the
coronary artery disease group (41% vs . 20%. p < 0.001)
. as
was the frequency of diabetes mellitus 1)2% vs . 3.2%, p <
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Table 1 . Clinical Characteristics of Patient and Control Groups
BM1 = holy nosy index Iweighl Ikgllheight (eml'- ) ; CAD -- coronary
ornery di,eare
; T -
cm-Jul
fur multiple r le .1. (Bonrerroni carteclioN.
0 .001) and smoking (67% vs . 28%, p < 0.1811). Body mass
index was 27
.79 ± 4
.08 in the coronary artery disease group
versus 27 .14 ± 3 .66 in the control group (p = 0.024) . After
correction for multiple t tests (Bonferroni correction), age
and body mass index were no longer significantly difcrc^ .t
Because of our previous finding (57) that sampling in
patients in the hospital can lead to a bias in lipoprotein
levels, especially for HDL cholesterol, we performed oro-
spective resampiing in 72 patients after hospital discharge
and ?6 weeks after cardiac catheterization. No significant
effect on total . LDL and VLDL cholesterol, plas,na iriglyc-
erides or apolipoprotein B concentrations was noted in the
out of hospital state compared with the hospital sampling .
However, as we have previously seen, HDL cholesterol and
apolipoprotein A-I were lower at the time of the catheteriza-
lion than in the out of hospital state (33 ± 9 vs . 37 ± 8 mg/dl,
p<0.001 and 105 ±23vs. 117 ±24mg/dl,is<0.001,
respectively) . On the basis of this sample (58) and previously
reported data (57) . we believed that a correction factor was
necessary to compare HDL cholesterol and apolipoprotein
A-1 values in the patient and control
groups
. The
increase in
HDL and apolipoprotein A-I concentrations observed out of
hospital was proportional to the Initial (in-hospital) values,
HDL cholesterol was thus increased by a factor of 1 .0916
and apolipoprotein A-I by 1 .101 for patients with coronary
artery disease who underwent sampling in the hospital at the
time of cardiac catheterization .
fedietsfion effect was also evaluated in patients with
coronary artery disease (Table 2) . Beta-blockers are known
to exert an effect on plasma lipupreetein levels (59-62) . Of
the 321 patients 113 (35%) were not and 206 (65%) were
taking a beta-blocker. There were no statistically significant
differences in total cholesterol or apolipoprotein B values in
these two subgroups ; however, patients taking a beta-
blocker had lower LDL cholesterol, HDL cholesterol and
apolipoprotein A-I concentrations and higher triglyceride
levels than did patients who were not taking such medication
(p < 0 .05) (Table 2) . Because the effects of beta-blockers on
plasma lipoprotein concentrations are significant and two-
thirds
of our patients were taking this class of medication,
we analyzed the patients with coronary artery disease as a
Patients With
CAD
In = 321)
Coexol aubioea
In -901) p Value P , Value
Ar.lye
50±7
49 , A n.046 0276
'A Male 10051 371 -
ueta .blarker b% 7'>£ <a.0ul 0.001
H yperteneia„ m 'A 2070 <0.001 0.1)01
Diabetes 12'7 0.1% c0.001 0.001
Snakcrs 671/1 28ek =0.001 0.001
OMI 27 .79 14 .08 27,14 a 3,66 0.024 0.144
'0vea11 results lrspressed in mgfdl) eurreclcd only for hospital effect
. nigh Jmaly lipoprotein 1HDLt cholesterol increased from 32 m 11110
35 = 11 mg/dl
(HDL x 1
.0916). Lipoprotein (al ILp (all was determined in 7601,1410 control ,ubjec19 and 256 male patients with err0narY errors disease
. Arolinonrntein A-1
(Apo A-1) increased from
HIT x 22
to I I I c
25 mg'd1 (Apo A-I
x
1 .1011 to compensate for hospial effect (see text rot details)
. Apo B =Apolipoprotein B :
LDL = low density lipopratein cholesterol: p1 Control lsubieclsvs
.Italic- wi,hmrCeotyanerydirease:p==patients with coronary arerydiseasemttaking
a bela-adrener&c blocker vs. those taking such medication : p' = control subjects vs- patients with coronary artery disease not taking a beta-blacker
: T coal =
total cholesterol : Tg = lriglyceride.s: VLDL = very low density lipoprotein cholesterol
.
group, then separated those who were and were not receiv-
ir
.2 hetis-btcaper rherap;. We ;!so 2 ;dsi21 triglyceride,
LDL cholesterol, HDL cholesterol, apolipoprotein B and
apolipoprotein A-I levels in patients taking a beta-blocker to
those patient who were not taking a beta-blocker . We
assumed that the differences observed between patients with
artu without beta-blocker therapy were 7o!ely due to the use
of
such medication .
Lipid, lipoprotein and
apolipoprotein levels (Tables 2 and
3) . To correct for a diet effect, total cholesterol, LDL
cholesterol and apolipoprotein B towels were increased by
6
.6%, as discussed . Uncorrected lipid, lipoprotein and apr-
lipoprotein levels are shown in Table 2
.
After adjustment for confounding variables, lipid and
lipoprotein cholesterol and apolipoprotein levels in patients
and control subjects were compared (Table 3) . The patients
with coronary artery disease had a
4
.7%
higher total choles-
Table 3
. Lipoprotein and Apolipoprotein Levels in Control Subjects and Patients With Coronary
Angry Disease
terol level
(224 ± 53 vs
. 214 = 36 mg/dl, p < 0.0011, 34%
higher triglyceride level
(189 - 95 vs . 141 ± 104 mgldl, p <
0.001) and 13% higher LDL cholesterol level (156 ± 51 vs .
138 ± 33 mg/dl, p < 0.001) ; they had a 22% lower HDL
cholesterol concentration (36 t_ i I vs . 45 ± 12 mg/dl, p <
0.001) . 16% lower apolipoprotein A-I l vt
: f! 14 `_ 26 ys . 136
1- 32 mgldl- p < 0 0011 . 25%p higher apolipnprolejn
8
level
(131 ± 37 vs. 108 ± 33 mg/dl, p < 0
.001)
and
34% higher
Lplal level (19 .9 ± 19 vs . 14 .9 s 17.5 mg/dl, p < 0.003)
.
Not
correcting for beta-blocker and diet effects significantly
alters the classification of lipid disorders in patients with
coronary artery disease on such medication (Table 2) .
Prevalence of lipoprotein abnormalities (Table
4). The cut
points used for lipoprotein abnormalities were the 90th
percentiles for age and gender according to the Lipid Re-
search Clinics data for total and LDL cholesterol and
triglyceride levels and the 10th percentile for HDL choles-
*As in Table 2
. trout cholesterol IT shot), law density lipoprotein ILDLI cholesterol, apolipoprotein A-1 (Apo
A-I) and apolipoprotein b (Apo BI adjusI.d IADJ) for beta-edrerergic blacker use and effects ofdiet Iran rear). p' _
control subjects vs. patients with coronary artery disease after adjustment for beta-adreneBic biockers and diet
effects . Abbreviations as in Table 2 .
Control
Grasp
la = 901)
Coronary Artery Disease Group (n = 320
Os-ti
p
After
ADJ+
P,
T ch0l 214 .7 36 211 x49 11.343
224 ,
53 10 .001
TS
141 ^_ IM IN A 96 <n.Nll 199- 05 -=0 .001
VLDL 28 a: 21 38 0 19 <0.001 38 ± 19 ±0 .001
LDL
138 ± 33 141 2 46 0.853 156 '- 51 <0 .001
HDL 45
x 12 35 ± 10 <0.001 36 0 1I <0 .001
Apo 8 108 ± 33 123 0 33 <0.001 131 ± 37 <0 .001
Apo A-1 136 x 32 111 x 25 <0.001 114 0 26 <0.001
Lp(al
14.9
0
17 .5 19.9 < 21 .5 <0.002 19.9 0 19 <0.003
JACC Vol.
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Table 2 .
Lipoprotein and Apollpoprctein Levels in Control Subjects and Patients Wilh Coronary Artery Disease : Effects of Beta.
Adrenergic Blocking Agents
Coroners Artery Disease Grmtp
Control
HIM Il OCker freatleenl
Group Overall- Or
on
la = 9011 no - 7311 p' In -
III
to - 2081 p p'
T clod
214 x 36 211 0 49 U.343 219 - 56
2U{ - 45 0 .059 0.18
T9 141 : 104 IRS a 96 <11001 177 ' 95 195 - 96
D.046 10.001
VLDL 28 c 21 3e d 19 <11,1101 15 - 19
39 x 19 0.037 101KI1
LDL
138 7 33 141 ' 46 (1853 139 - 39
137 x 40 0.034 <0.01
HDL 45 e 12
35 ' 10 <0 1911 37
-
12 34 -_ 9 0,023
10 .001
An . B 108 - 33 123 * 33 <0 .IM11 - 74
1 23 0 35 0.336 :0.1101
Apo A-1 136 ± 32 111 -'5 <11
.111 114 : 27 108 0 24 0.016 <0
.001
LOW 14,9 17,S
19,9
-
21 .5 ..0 .15!, 1, 1 x 16 17 .0 0 19 0.378 <001
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Table 4. Prevalence of Llpoprctem Abnornealnlos in Paucnls With
Premalwe Coronary Artery Disease
'After adjustment for sampling. bola 'edrenersie blockers and diel . TIE
glycerida (To) level >9teh
percentile . Low density liroprmein 1 LDL/ dOcile-
lerol >90th percenlile and high deal ply lipoprotein (HDLI clnlesterol <10tte
percenlile 1>901h percentile for age and ers matched LRC values for 'rg and
LDL ction-,rot : <10th percentilef r HDL : apol'lpoprorent B [Apo 01 >9011)
percenllc
. Apotipoprolein A-I (Apo A-II <10th percentile, based on the
Framiniti m Heart Smdyl . Presence of familial hypenh01esierobnds in 44
721 Ifregeency 0
.0125). 1p < 0005 : fp < 0.05 . Abbreviations as in Table 2I
terol (71) . For apolipoproteins B and A-I, the values were
derived from our control group of 901 men from the
Framingham Heart Study free of clinical manifestations of
coronary artery disease . The 90th percentile for apolipopro-
tein H and the 10th percentile roe apolipoprotein A-I were
chosen as cut points. Based on a slightly smaller sample of
control subjects (n = 760), the 90th percentile for Lp(a) was
determined al
38.8 all
The most frequeotr abnormality observed was ion, HDL
cholesterol (hypoalphalipoproteinemia) after correction for
hospital and medication effeots
. The next most common
phenotype was elevated LDL cholesterol either alone or in
combination with elevated triglycerides or reduced HDL
cholesterol. or both . The combination of hypertriglyeeri-
Tahk 5. Corelelinn Mat-ix
of Lipoproteins and Apolipoproteins in Potion> With Premature Coronary Artery Disease (n - 321) and
Control Subjects (n = 901)
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demia and decrensed HDL cholesterol was also significantly
higher in patients with coronary artery disease . The relation
between hypertdglyceridemia and low HDL cholesterol has
long been known (5) .
The prevalence of elevated Lp(a)
>38 .8 mgldl was higher in patients (15 .8%) than in control
subjects (10%, p < 0.05 )
.
In the coronary artery disease
group. four cases of heterozygous familial hypercholesterol-
emia with tendinous xanthomas were noted (estimated fre-
quency 00125). In the control group, two patients had a
cholesterol level >350
mg/dl
with LDL cholesterol level
95th percentile .
Based on the 90th percentile for triglycerides and LDL
cholesterol and the 10th percentile for HDL cholesterol,
38.9% of patients had no abnormality compared with 73% of
control subjects (p < 0.001) (Table 4). A slightly higher
proportion of patients had a significant lipid abnormality
while taking a beta-blocker than while not taking such
medication (64.4% vs . 57 .5%. data not shown) . The corre-
lations among the lipid variables are shown in Table 5 .
The reinlina between LDL cholesterol and plasma apo-
lipoprotein B on n scarrergram (data not shown) reveals that
in some patients with coronary artery disease, elevation of
apolipoprotein B occurs without a proportional elevation in
LDL cholesterol . This observation has been previously
made by Sniderman et al . (19)for LDL apolipoprotein B (72)
and LDL cholesterol
. The prevalence of elevated apolipo-
protein B with normal LDL cholesterol (using the 90th
percentile for both LDL and apolipoprotein B levels) was
19 .8% compared with 8 .4% in the control group (p < 0 .005) .
However, only 10
.7% of the patients with coronary artery
disease had elevated apolipoprotein B with normal (that is,
<90th percentile) levels of triglycerides and LDL choles-
terol. This provides an index of the frequency of hyperapo-
betalipoproteinemia (19) in this cohort .
Discriminant analysis (Table 6). Discriminant analysis
reveals that conventional risk factors allow for an excellent
discrimination between patients and control subjects (Table
6A) . When apolipoprotein variables were entered into the
statistical model and triglycerides, total cholesterol, LDL
cholestelvl and HDL cholesterol were removed, apolipopro-
tein B conferred better discrimination than did LDL choler .
'Lipopraein (a) ILp (a)1 hared on 76ocontrol mobjeas and
256 pill ants with cpronueyartery disease . 7p < 0.01.4p < 0 .001 .
Data me Spearman correlation
caemcienm. Lower Ief[ = control subjects : upper right = patients with coronary artery
disease . Abbreviations as in Table 2.
7,Clrol
T8
VLDL LDL Ill
ApuB ApoA . Lplat'
T Chat 0 .2671
0157 : 0 .9230 0.183' 0 .7201 0.279, -0.030
re
0.3109
0.997
.
-0 078 -0.260" 03179 0.007 -0.166
VLDL 0.3969
09701 -0045 -0.259" 0315t 0001 -0.166
LDL 0,8571
-0.102'
-0
.077 0.096 0 .6441 0.153' -0.006
HDL 0.005 -0.4201 -0 .427
-00891 -0 .040 0.6701 0.093
Apo B 0.6731 03461 D .3g7'
0.5699 -2 .2991 0.071 -0.160
Apo A4 0.1351 -0.1091 -0 .186+
-0.008 0 .7561 -0 .093' 0.056
Lp(a)
0.032 -0.147 -0 .147 0.135 ( .091 ¢041
0.039
Coined Creep
In = 901)
Coronary Anery COO re
Gmopln=7211
Overall After A01'
HDL 4 .479
27
.1990
19.3"40
Tg*HDL 4,27
13.7990 9.79, ;
Tg 8 .5% 9.7% 9.94
LDL 9 .0% 4.7>0 12.1019
LDL* HDL 0 .301 4.791 3.7015
Tg+LDL 09% 1 .69 3.1' :
TVLDL+HDL 112% 0501 9,1'
. :
DyApidcaic 27.07. 62.491'
Normal 71091 170`41 78'
Al
HD1 . 9 .009 46.11 76.1'
Alt
t0 13.301 25 .99" 25.9914
All 1OL 9.901% 11 .90 220013
Atet B 11.0%c 21 .199 0 36An
r
ApoA-l
IU.7% 37.0991 36.49)4
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Table 6 . Stepwise
M16--t Analysis
sop
	
VatabN
Part,aW Model r' p VaSac
A: Lipids and Lipppoyt2irc
I
Smoking 0.171 0371 0.702
2 HyPrnensmn 0.114 0,185 9,701
3
HDL 0,994 0.579 0.001
4
Diabetes 0.050 .629 0001
5 LDL 0.910
0 .631 0_ 00
6 Lplai 0.m] os10 01591
B : lipids, Lipopoleins and Apoltpopo5v ss'
I Smoking 0.37E
0 .372 0 .001
2 Apu A-I 0.107 0 .479
goo]
3 Hyrenanioa 0.004 0.373 0001
4 APa B 0.049 0.622 0.0111
5 Diabetes 0.030 0.652
O.OUI
6 Ip1at 11001 0655 0006
Based-lteccnao!
subjects
and 256 mar viv -11-y1rry sory dill-.
Abbrevietirv. a s T.64 2.
terol between patients and control subjects (Table 6B)
.
Triglyceride concentrations appear to offer significant
univariate discrimination between patients and control sub-
jects, but were excluded from the made] with multivariate
analysis. Mean and median Lp(al levels were higher in
patients than in control subjects ; Lp(a) is an independent
risk factor for the development of coronary artery disease .
The second model that included traditional risk factors
revealed that smoking, hypertension, apolipoprotein A-I,
apolipoprotein R, Lp(a) and diabetes were all significantly
associated with the presence of coronary artery disease
.
The frequency distributions for adjusted levels
of LDL
cholesterol (Fig. IA), apelipoprotein B (Fig. Ill), HDL
cholesterol (Fig . IC), apolipoprotein A-1 (Fig . ID), triglyc-
erides (Fig. Ill) and Lp(a) (Fig. IF) are shown for patients
and control subjects.
Discussion
identification of patients at risk for developing coronary
artery direaax. This poses a daunting problem
. Because of
the nmhifactoriat etiology of the disorder in which environ-
mental, genetic and nutritional aspects are so closely inter-
related, it is becoming increasingly difficult to provide a
cost-effective assessment of risk in the general population .
The recently published recommendations of the National
Cholesterol Education Program (45) have focused on total
and LDL cholesterol as a basis for screening and treatment .
Our data suggest that total and LDL cholesterol may not be
the best discriminants for the presence of coronary artery
disease despite the strong association between elevated
cholesterol and the development of coronary artery disease
in cross-sectional population studies and prospective epide-
miologic studies. Although total cholesterol remains a good
mariner for coronary artery disease between populations
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it,Z .20) . HDL cholesterol appears
i0 be a better predictor
within populations.
The present study shows that total and LDL cholesterol
do not differ significantly between patients and control
subjects it the confounding effects of diet and beta-blockers
(73) are not taken into account, LDL cholesterol, however .
is higher in patients not taking beta-Mockers than in control
subjects and patients with coronary artery disease appear to
have a healthier diet than normal control subjects .
Triglscerililm The association between triglyceride con-
centrations and coronary atherosclerosis deserves close
scrutiny, We observed a significantly hig ;rer triglyceride
cuacenlration in paliems with coronary artery disease than
in control subjects, o' bserratiun previously noted (74,75),
bat not in large, prospective epidemiologic studies
. The
negative coreclation between elevated triglycerides and de-
creased HDL cholesterol levels makes it difficult to consider
triglyceride levels independently
. B does appear that high
triglyceride levels are associated with increased cardiovas-
cular risk when they are associated with elevated levels of
LDL cholesterol or plasma apotipoproteis B (type III, hy-
perlipoproteinemia or hyperapoheralipoproteinemia (761) or
low HDL cholesterol levels, alone or in combination . Hy-
perlriglyceridemia alone, however, is not significantly more
frequent in patients than control subjects, indicating that it is
the combination of hypertriglyceridemia with elevated LDL
or reduced H DL cholesterol
. or both, that confers additional
cardiovascular risk.
The data presented here show the importance of consid-
ering confounding variables, not only with respect to indi-
vidual patients, but when interpreting epideutiologic studies
dealing with lipids and coronary atherosclerosis . The high
prevalence of dyslipldemias in the coronary artery disease
group, irrespective of confounding variables, strongly sup-
ports the concept of the role or lipid disorders in the
pathogenesis or coronary at erosclerosis . Diverse mecha-
nisms will undoubtedly underlie must lipid disorders ; for the
purpose of discussion, these disorders will be grouped into
disorders of LDL, triglycerides, HDL and Lp(a).
Elevated LDL cislsled (type HA by i ).
in this study, the prevalence of elevated LDL cholesterol in
patients was 22.4% vs . 9,9% in control subjects (p < 0 .05)
(Table 4) after correction for confounding variables . If those
variables are not taken into account, mean levels of LDL
cholesterol and the prevalence of elevated LDL cholesterol
are underestimated. The prevalence of elevated LDL
cho-
lesterol
was 11,9% in patients before correction . The prev-
alence d LDL cholesterol >90th percentile without other
abnormalities was 12.3% vs . 9% in the control group.
Heterozygems familial hypeecholesteenlemia (as defined by
markedly elevated LDL cholesterol levels [>95th percen-
tile], the presence of tendinouo xanthomas . familial segrega-
tion and premature coronary artery disease) was present in 4
of 321 patients (prevalence 0 .0125) . In the control group, two
patients had total cholesterol levels >350 mgldl with LDL
cholesterol >95th percentile (prevalence 0.002). Although
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Figure 1 .
Frequency distribution of LDL cholesterol fLDL-CI (Al,
apolipoprotein (Apo) B IS), HDLcholestered IHDLC)
(C) . apolipo-
protein (Apo) A-1 IDL Iriglycerides (E) and Lp(a)
IF) in control
subjects (lines) and m
c
with coronary artery dime- (CAD)
(hatched ban). Data are adjusted (adj.) for diet . sampling
and
bela-blacker use . ELISA = enzyme-linked immunosorbem assayss
accurate estimates oft he prevalence of familial by perc holes-
irrolemia due to a functional abnormality of the LDL
raceptor do not exist, the frequency varies from 0 .002 (I of
5a0) in [he general population to 0 .0031 (I of 270) in
populations with a founder effect, such as the French Cana-
diaos or Afrikanners in South Africa 177,781
.
Combined hyperllpidemia (types I® and IV hyperlipepro-
binemias). The frequency of hypenriglyceridemia (without
crude iipupratein abnormalities) was 9 .7% in the patient
group versus 8 .5% (close to the expected frequency of
8 .1%)
in the control group (p = NS) . Hypertriglyceridemia without
elevated LDL cholesterol or decreased HDL cholesterol
was not seen more frequently in patients with premature
coronary artery disease in this study . The frequency of
elevated triglycerides associated with low HDL cholesterol
was higher than expected in the control group if both were
independent of each other (which is not the case) . Hyper-
triglyceridemia combined with hypoelphalipoproteinemia is
common in patients with coronary artery disease (Table 4)
.
The frequency of elevated Iriglycerides and LDL choles-
terol, with or without decreased HDL cholesterol, was
greater in patients on a beta-blocker than those not taking
such medication .
Hypoalphalipoprntelnemla (low HDI. ehokslerol). In the
present study, the most common abnormality was hypoat-
phalipoproteinemia, cirheralane (19 .3% vs . 4.4%, p < 0 .001)
or associated with an elevated triglyceride concentration
(9 .7% vs
. 4 .2%. patients vs . control subjects . p < 0.001).
Bath the use of a beta-blacker and in-hospital sampling
cause an overestimation of the prevalence of hypoalpha-
lipaproteinemia, as does the higher proportion of smokers in
our patient group (Table 1). The frequency of "pure"
hypoalphalipoproteinemia
is lowerthan the expected level in
the control group (4 .459) and the combined disorder of
hypcetrigtyceridctrua with tow HDL cholesterol is higher
than expected (4.2%)
.
These observation underlie the close
inverse association of triglycerides and HDL cholesterol. In
the coronary artery disease group, 36.1% had low HDL
cholesterol alone
or in combination with other lipoprotein
abnormalities compared with 9% in the control group- This
represents a fourfold increase over values in control sub-
jects
. Ow data are consistent with previously published
data . In
several studies (14,27,35,37,40,41,43), the mean
HDL cholesterol level
:vas lower than reported in the
present study . None of these studies has reported the
prevalence of low HDL cholesterol in their patients based on
the 10th percentile for age and gender
. When considering the
cut points of the National Cholesterol Education Program
(45),35% (113 of 321) of our patients had a total cholesterol
OENEST ET AL .
	
799
LIrOPn11TI
:INS IN CORONARY ARTERY DISEASE
Icvcl <200 megidl
. Of those, 73% (83 of 113) had a HDL
cholesterol lcuel <35 mgrdt
. Thus, despite a total cholesterol
lead considered within the desirable range. many patients
had a significant dyslipidemia,
Lp(a) excess. No large population norms are as yet avail-
able for Lpial
. In [his study Lp(a) levels were higher in the
patient group than in the control group and a prevalence of
Lpla) X38 .8 mgtdl was also higher in the coronary artery
disease group . The frequency distribution of Lpla) is skewed
to the right both in patients and in control subjects . The
physiologic role of Lplat has not been elucidated, but Lp(m
may interfere with i ntravascular thromholysis and inhibit the
streptokinase-mediated mrroersic ; of plasmin from plasmi-
nogen
. Furthermore, Lp(a) is found within atherosclerotic
plaque and may contribute to cholesterol ester accumulation
within the plaque (56)
.
Apolipoprotein B. It has been suggested that apolipopro-
rein B and apolipoprotein A-I serve as better discriminators
for the presence of coronary artery disease than LDL or
HDL cholesterol . The level of apolipoprotein B was in-
creased in our patients (Table 3) and the value was not
influenced by sampling effect or beiablocker use . Further-
more, the frequency of elevated apolipoproteie B in the
coronary artery disease group is nearly three times that in
the control group after correction for confounders
. Our
assay does not measure LDL apolilactIptiotein
B, but does
measure total plasma apolipoprotein B . Therefore, we could
not reliably establish the prevalence ofhyperapobetalipopro-
teinemia (elevated apolipoprotein B in LDL) as originally
defined 019) in
patients with coronary atherosclerosis be-
cause our assay for apolipoprotein B measures total plasma
apolipnprntein B in comparison with the radial immunodif-
fusion (RID) assay that measures LDL apolipoprotein B
(72) . However, in nermolipidemic patients (<90th percentile
fur triglyeerides and LDL cholesterol), 1D
.7% have an ele-
vated apulipuprotein B alone compared with 4.5% in the
control group
. Apolipoprolein B nary reflect the number of
apolipoprolein B-containing particles and thus provides bet-
terdiscrinrfnation than the cholesterol content of VLDL and
LDL particles .
Apolipuprotei
Ad. Levels of apolipoprotein A-I were
decreased in patients with coronary artery disease to a
degree similar to the reduction in HDL cholesterol . The
prevalence of low apolipopotein A-f (<10(h percentile) in
patients was nearly 3 .5 times that found in control subjects
(after correction for biases) . Comparing the two by stepwise
discriminnnt analysis . apolipoprotein A-I appears slightly
better than HDL
cholesterol
in differentiating patients from
control subjects.
In this case-control study of 321 men with angiographi-
cally documented coronary artery disease, plasma levels of
cholesterol, LDL cholesterol, triglycerides, apolipoprotein
B and Lp(a) were increased and levels of HDL cholesterol
ad apolipopratein A-I were decreased compared with a
group of healthy middle-aged men with no clinical manifes-
tations of coronary atherosclerosis
. The prevalence of lipo-
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protein abnormalities was confounded by in-hospital sam-
pling bias, dietary changes and use of beta-blockers . When
these were taken into account, the most common abnormal-
ities include hyimatphalipoproteinemia, combined hyper ti-
glyceridemia with hypoalphalipoproteinemia
. elevated Lpla)
and elevated L'DL cholesterol . The use of beta-blockers in
patients results in overestimation of the frequency of hyper-
triglyceridemia and hypoalphalipoproteinumia and underes-
iimarion of the frequency of elevated LDL cholesterol .
Conclusions. This study revealed et high prevalence of
dyslipidemias in patients with coronary artery disease . Clin-
ical trials (79-83) have demonstrated that a reduction in
elevated LDL cholesterol is associated with a reduction in
cardiovascular mortality
. The current guidelines of the Na-
tional Cholesterol Education Program (45) are directed at the
screening and treatment ofelevated LDL cholesterol levels .
The prevalence of HDL cholesterol and triglyceride abnor-
malities Ives greater in the coronary artery disease group
than in the control group and accounted for >51)% of the
lipoprotein abnormalities identified in this study
. We recom-
mend that adult men with coronary artery disease hate a
determination of HDL cholesterol, regardless of total cho-
lesterol, and that healthy men have a determination
of
Higlycerides and HDL cholesterol if the total cholesterol is
m200 mgldl
. In addition, our data suggest that apolipoproteln
13, apolipoprotein
A-I and Lp(a) are slightly better discrim-
inators between patients and control subjects than am con-
ventional lipoprotein variables .
To our knowledge, no other case-control studies in patients
with coronary artery disease have taken into account the
effects of
sampling biases, medications and differences in diet
compared with a control group, However, prospective studies
have shown the importance ofelevated total and LDL chC:es-
terd in patients with coronary artery disease . Our study
suggests that once these variables are taken into account, our
results closely match those of prospective studies with regard
to lipoproicin cholesterol levels. Moreover, the data point to
the concept that in patients with established coronary artery
disease more aggressive efforts should he made to lower LDL
cholesterol levels to < 100
mg1dl and consideration should also
be dueled to using agents known to raise HDL constituents
(for
-pee, macin, fenohbcate, gernlbrozil, 6ilnvasialin, tov-
astatin and pmvasatin)
.
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